Third Harmonic Bio, Inc. (THRD) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Third Harmonic Bio (THRD) attracts leading immunologists through a flexible corporate environment and stock option programs, ensuring high R&D freedom. This EV/EBITDA chart, reflecting valuation dynamics with a value of , complements data on the development of oral treatments for skin inflammation as alternatives to injections. Due to its independence from macroeconomic trends and stable demand for unique therapies, Third Harmonic Bio (THRD) serves as a reliable defensive asset.
thirdharmonicbio.com - analytical breakdowns and key metrics (THRD)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Third Harmonic Bio|THRD - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Third Harmonic Bio, Inc.|THRD - Company Cumulative Debt|Debt to Book Value Third Harmonic Bio Inc|THRD - Amount of Long-Term Liabilities|Company Short-Term Debts Third Harmonic Bio|Quick Ratio thirdharmonicbio.com
- business earnings and investment ratios data:
THRD - Net Financial Result|Expected Profit Third Harmonic Bio|THRD - Company Value to Net Income|Forward P/E Multiple Third Harmonic Bio|THRD - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Third Harmonic Bio Inc|THRD - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Third Harmonic Bio|THRD - Earnings per share for the trailing year|Quarterly EPS earnings growth thirdharmonicbio.com|THRD - Earnings growth in current year|Net earnings per share growth forecast for next year Third Harmonic Bio
Initial company analysis:Third Harmonic Bio, Inc (THRD)
To protect a portfolio, investors select assets with sustainable operating leverage and a transparent capital structure. Third Harmonic Bio (THRD), competing in the dermatological drug sector, depends on the success of clinical trials, which makes valuation critical. By analyzing the company's EV/EBITDA ratio, an investor compares the enterprise value, including debt, against its actual earnings before interest, taxes, depreciation, and amortization to determine whether the asset is undervalued or overpriced.
Competing companies
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|Dianthus Corp - Enterprise Value to Operating Income Before Depreciation Ratio|PHVS: EV/EBITDA Multiple|AbCellera - Business Value to Operating Income Before Depreciation|TRML (Tourmaline Bio) - EV/EBITDA Multiple|Precigen Inc (PGEN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming (PHAR)|NKTR (Nektar Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple UPB (Upstream Bio Inc)|ZBIO: Enterprise Value to Operating Income Before Depreciation|IMNM: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GOSS (Gossamer Bio Inc)|KALV: EV/EBITDA Multiple|Septerna Pharma - Business Value to Operating Income Before Depreciation|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|EV/EBITDA Multiple savarapharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Pharmaceuticals, Inc. (RIGL)|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Astria Pharma ATXS|ENGN - Enterprise Value to EBITDA Ratio|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Aerovate Therapeutics Inc|Aclaris Therapeutics, Inc. (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation KYTX|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|Cabaletta Bio Inc (CABA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple VTYX|Enterprise Value to EBITDA Ratio theratech.com THTX|Avalo Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ELDN|Agenus Inc - EV/EBITDA Multiple|CLYM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ZURA: EV/EBITDA Multiple|ATYR - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adagene Inc|Company Value to EBITDA Ikena Oncology, Inc. IMA|Enterprise Value to EBITDA Ratio STTK (Shattuck Labs, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio EQ|EV/EBITDA Multiple CNTB (Connect Biopharma Holdings Limited)|Business Value to Operating Income Before Depreciation IMUX|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation IFRX (InflaRx N.V.)|XFOR: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ACET|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|inmunebio.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BRNS|KZR (Kezar Life Sciences Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SABS (SAB Biotherapeutics, Inc)|EV/EBITDA Multiple Akari Therapeutics, Plc AKTX|ENLV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation QTTB (Q32 Bio Inc.)|GeoVax (GOVX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Edesa Biotech Inc|IBIO (iBio Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Carisma Tx|Enterprise Value to EBITDA Ratio XTLB (XTL Biopharmaceuticals)|BOLT (boltbio.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple HCWB (HCW Biologics)|Total Company Value to Operating Income Before Depreciation Ratio Aptevo Therapeutics, Inc. (APVO)|AIM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Aditxt (ADTX) - Enterprise Value to EBITDA Ratio|GRI Bio, Inc. (GRI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio xortx.com|Enterprise Value to EBITDA Ratio HIND|EV/EBITDA Multiple Revelation Biosciences Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Indaptus (INDP)|BiondVax Pharmaceuticals - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple CALI (CalciMedica)|Affimed NV (AFMD) - Company Value to EBITDA|ALLK: Enterprise Value to EBITDA Ratio|HOOKIPA Pharma Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|IGMS: EV/EBITDA Multiple|iTeos Pharma - Business Value to Operating Income Before Depreciation|OCEA (Ocean Biomedical, Inc.) - EV/EBITDA Multiple|tcbiopharm.com (TCBP) - Total Company Value to Operating Income Before Depreciation Ratio
